Viscous composition for treating ischemia
A composition and ischemic technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, blood diseases, etc., can solve problems such as blood blockage and vascular blockage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0043] Example 1: Diabetic Lower Extremity Ischemia Mouse Model
[0044] The source of C57BL / 6 strain male mice was the Experimental Animal Center of National Cheng Kung University (NCKU) or BioLASCO Taiwan Co., Ltd. (BioLASCO Taiwan Co., Ltd.). Mice were kept in the animal room of National Cheng Kung University Biotechnology Institute for at least one week so that they could adapt to the environment before conducting experiments. All experiments performed were pre-approved by the Institutional Animal Care Committee (IACUC) of NCKU.
[0045] This experimental animal model was established to study the treatment of lower limb ischemia. Mice aged 6 months or older were treated with a 50 mg / kg body weight streptozotocin (STZ) solution to induce type I diabetes in order to exhibit the characteristics of advanced age and less regenerable damaged diabetic tissue. Because low blood sugar levels in mice could interfere with the results, mice with blood sugar levels in the range of ...
Embodiment 2
[0051] Example 2: Hyaluronic Acid Viscosity Test
[0052] Compositions containing different concentrations of hyaluronic acid with different molecular weights were prepared.
[0053]The viscosity of the pharmaceutical composition was measured using a DV2TRV Viscometer (DV2TRV Viscometer) (Brookfield, USA) according to the manual. Select the appropriate rotor (CPE40 or CPE52) according to the viscosity. Before the measurement, the machine was calibrated and set to run at 20 rpm for 1 minute at room temperature 25°C. Transfer 500 μl of each sample to the sample plate with a viscosity pipette, and press the operation key to start testing the viscosity of the sample. The viscosity of 5mg / ml hyaluronic acid with molecular weights of 1560kDa, 700kDa and 2,000kDa was measured, and the results are shown in Table 2. The viscosity of hyaluronic acid having an average molecular weight of 1,560 kDa at 5 mg / ml was taken as a reference, and the viscosities of various concentrations of ...
Embodiment 3
[0063] Example 3: Pharmaceutical composition containing vascular endothelial growth factor (VEGF)
[0064] Mice were administered a composition (DIV) containing 5 mg / ml of hyaluronic acid with an average molecular weight of 1,560 kDa and VEGF (DIV), and the effects of the composition on lower limbs and blood flow were evaluated as described in Example 1 above. Diabetic mice not treated with the composition after surgery were used as controls. VEGF drugs have been described in the literature to have angiogenic effects. The maximum and minimum effective doses for human VEGF were converted to mouse doses based on body weight.
[0065] Appearance ratings are shown in figure 1 . Administration of 100 [mu]l DIV is equivalent to administering 3.125 ng / g body weight of VEGF to mice. Administration of VEGF (DIV2) at 3.125 ng / g to mice resulted in higher appearance scores compared to controls. At doses of VEGF down to 0.3 ng / g (DIV1 ), lower appearance scores were observed than i...
PUM
| Property | Measurement | Unit |
|---|---|---|
| Average molecular weight | aaaaa | aaaaa |
| Average molecular weight | aaaaa | aaaaa |
| Average molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More